Health Care [ 12/12 ] | Biotechnology [ 58/74 ]
NASDAQ | Common Stock
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis.
The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008.
Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 20, 25 | 0.02 Increased by +116.67% | -0.00 Increased by +2.96 K% |
| Oct 31, 24 | -0.00 Decreased by -111.33% | -0.05 Increased by +93.20% |
| Aug 1, 24 | -0.07 Increased by +12.50% | -0.11 Increased by +36.36% |
| May 2, 24 | -0.11 Increased by +15.38% | -0.15 Increased by +26.67% |
| Feb 22, 24 | -0.12 Decreased by -300.00% | -0.09 Decreased by -33.33% |
| Oct 31, 23 | 0.03 Increased by +121.43% | -0.11 Increased by +127.27% |
| Aug 2, 23 | -0.08 Increased by +57.89% | -0.11 Increased by +27.27% |
| May 3, 23 | -0.13 Increased by +38.10% | -0.10 Decreased by -30.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 116.13 M Increased by +237.95% | 4.64 M Increased by +116.13% | Increased by +4.00% Increased by +104.77% |
| Sep 30, 24 | 98.24 M Increased by +74.21% | -809.00 K Decreased by -112.20% | Decreased by -0.82% Decreased by -107.01% |
| Jun 30, 24 | 73.22 M Increased by +227.86% | -16.45 M Increased by +3.90% | Decreased by -22.47% Increased by +70.69% |
| Mar 31, 24 | 46.02 M Increased by +304.81% | -26.52 M Increased by +0.95% | Decreased by -57.62% Increased by +75.53% |
| Dec 31, 23 | 34.36 M Decreased by -22.22% | -28.80 M Decreased by -369.30% | Decreased by -83.82% Decreased by -446.22% |
| Sep 30, 23 | 56.39 M Increased by +1.03 K% | 6.63 M Increased by +127.73% | Increased by +11.76% Increased by +102.45% |
| Jun 30, 23 | 22.33 M Increased by +784.13% | -17.12 M Increased by +36.44% | Decreased by -76.66% Increased by +92.81% |
| Mar 31, 23 | 11.37 M Increased by +2.33 K% | -26.77 M Increased by +4.62% | Decreased by -235.49% Increased by +96.07% |